TOKYO, Japan & MUNICH, Germany I4, 2024 I Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the ...

Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales – – Jemincare is currently conducting ...

MD, USA I3, 2024 I Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide ...

HENDERSON, NV, USA I3, 2024 I Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel ...

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle ...

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The ...

CHENGDU, China I December 23, 2024 I Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the “NMPA”) of China has recently approved the supplemental New ...

Approval based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years In the trial, Tagrisso reduced the risk of disease progression ...

SHANGHAI, China I December 22, 2024 I CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, ...

CARLSBAD, CA, USA I 19, 2024 I Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has ...

JENA, Germany I, 2024 I InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics ...

Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically ...